Kailera Therapeutics Inc
KLRAHealthcare|Biotechnology|USA
$20.68
-0.33 (-1.57%)
Financials
Financial Snapshot
Market Cap
$2.68B
Enterprise Value
$535.3M
Revenue (TTM)
$0.00
Net Income (TTM)
$-149.0M
Cash & Equivalents
—
Net Cash/Share
$-4.26
Free Cash Flow (TTM)
$-122.3M
Operating CF (TTM)
$-120.2M
Debt/Equity
-0.03
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$30.1M
Monthly Burn
$10.0M
Est. Runway
—
| Metric | Trend | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Cash & Investments | $175.2M | $546.1M | $546.1M | |
| Operating Cash Flow | $0.00 | $-120.2M | $-120.2M | |
| Free Cash Flow | $0.00 | $-122.3M | $-122.3M | |
| Capital Expenditure | $0.00 | $-2.1M | $-2.1M | |
| Financing Cash Flow | $0.00 | $598.7M | $598.7M |
R&D Spending
R&D (TTM)
$109.1M
R&D Intensity
—
R&D Growth YoY
+0.0%
| Metric | Trend | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $109.1M | $109.1M | |
| R&D % of Revenue | — | — | — | |
| SG&A | $0.00 | $49.2M | $49.2M |
Income Statement
| Metric | Trend | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | |
| R&D | $0.00 | $109.1M | $109.1M | |
| SG&A | $0.00 | $49.2M | $49.2M | |
| Operating Income | $0.00 | $-158.3M | $-158.3M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $0.00 | $-149.0M | $-149.0M | |
| Net Income | $0.00 | $-149.0M | $-149.0M | |
| EPS (Diluted) | 0.00 | -1.26 | -1.26 | |
| EBITDA | $0.00 | $-158.0M | $-158.0M | |
| Shares Out. (M) | - | 117.95 | 117.95 |
Balance Sheet
| Metric | Trend | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Cash & Equivalents | $175.2M | $160.3M | $160.3M | |
| Marketable Securities | $0.00 | $385.8M | $385.8M | |
| Total Current Assets | $177.6M | $557.5M | $557.5M | |
| Total Assets | $178.4M | $692.3M | $692.3M | |
| Total Current Liabilities | $6.9M | $46.4M | $46.4M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $397.2M | $1.05B | $1.05B | |
| Stockholders' Equity | $-218.8M | $-356.5M | $-356.5M | |
| Retained Earnings | $-219.7M | $-368.7M | $-368.7M |
Cash Flow Statement
| Metric | Trend | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Operating Cash Flow | $0.00 | $-120.2M | $-120.2M | |
| Capital Expenditure | $0.00 | $-2.1M | $-2.1M | |
| Free Cash Flow | $0.00 | $-122.3M | $-122.3M | |
| Investing Cash Flow | $0.00 | $-492.6M | $-492.6M | |
| Financing Cash Flow | $0.00 | $598.7M | $598.7M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $100.0M | $100.0M | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $10.9M | $10.9M | |
| Net Change in Cash | $0.00 | $-14.2M | $-14.2M |
Dilution Tracker
Shares Outstanding
118M
5-Year Share Growth
—
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Shares Out. (M) | - | 117.95 | 117.95 | |
| YoY Change % | — | — | 0.0% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $10.9M | $10.9M |
Margins & Profitability
| Metric | Trend | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | - | |
| Net Margin % | 0.0% | 0.0% | - | |
| EBITDA Margin % | 0.0% | 0.0% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | |
| ROE % | 0.0% | 0.0% | 0.0% | |
| ROA % | 0.0% | -34.2% | -34.2% | |
| R&D / Revenue | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S—
Historical— / — / —
Industry Med.9.49
P/B—
Historical— / — / —
Industry Med.2.93
EV/EBITDA-13.74
Historical-13.74 / — / —
Industry Med.13.02
EV/Revenue—
Historical— / — / —
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
| Metric | Trend | 2024 | 2025 | TTM |
|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | |
| PS Ratio | - | - | 0.00 | |
| PB Ratio | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA | 0.00 | 0.00 | -13.74 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
N/A
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $0.00M | $0.00M | $0.00M |
| Net Income | $-458.17M | $-561.40M | $-590.43M |
| EPS | -3.03 | -3.24 | -2.92 |
| Book Value per Share | 5.97 | 2.38 | 5.54 |
| Operating Cash Flow per Share | -2.42 | -2.83 | -2.00 |
| Operating CF | $-285.44M | $-333.80M | $-235.90M |